NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $104.71 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$104.75 +0.04 (+0.04%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$102.25▼$106.5750-Day Range$99.25▼$117.6052-Week Range$74.50▼$122.20Volume573,720 shsAverage Volume438,820 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/APrice Target$141.12Consensus RatingModerate Buy Company Overview Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s research is centered on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance. Rhythm’s primary product is IMCIVREE (setmelanotide), an MC4R agonist. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 2 years old with obesity and certain genetically confirmed conditions affecting the MC4R pathway, including pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1 and leptin receptor deficiencies, as well as Bardet-Biedl syndrome. The company is also advancing research intended to expand treatment options for additional rare metabolic diseases. Rhythm was founded in 2008 and is headquartered in Boston, Massachusetts. Its commercial and development activities primarily serve patients in the United States and other international markets where IMCIVREE has received regulatory authorization. David R. Meeker has served as the company’s chief executive officer and chairman.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 523rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on no strong buy ratings, 15 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialRhythm Pharmaceuticals has a consensus price target of $141.12, representing about 34.8% upside from its current price of $104.71.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -33.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -33.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 50.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.98% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 21.89, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 1.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.57 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest1 people have searched for RYTM on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,374,837.00 in company stock.Percentage Held by Insiders5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by InstitutionsRhythm Pharmaceuticals has minimal institutional ownership at this time.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesHead-To-Head Survey: Generate Biomedicines (NASDAQ:GENB) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM)September 12 at 2:15 AM | americanbankingnews.comRhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology MeetingSeptember 11 at 8:19 PM | marketscreener.comMThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.September 14 at 1:00 AM | Reagan Gold Group (Ad)Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology MeetingSeptember 10, 2026 | globenewswire.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 10, 2026 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $6,620,146.04 in StockSeptember 2, 2026 | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 5,079 SharesAugust 18, 2026 | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares of StockAugust 15, 2026 | insidertrades.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $107.04 at the beginning of the year. Since then, RYTM shares have decreased by 2.2% and is now trading at $104.71. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.08. The business's quarterly revenue was up 46.9% on a year-over-year basis. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $106 million in an IPO on Thursday, October 5th 2017. The company issued 7,050,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional shareholders of Rhythm Pharmaceuticals include California State Teachers Retirement System (10.37%), BlackRock Inc. (8.98%), Primecap Management Co. CA (4.62%) and Jupiter Topco LLC (1.35%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Jennifer Kayden Lee, Pamela J Cramer, Joseph Shulman, Lynn A Tetrault, Jennifer L Good, Alastair Garfield and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today9/13/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RYTM's financial health is in the Green zone, according to TradeSmith. RYTM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees414Year Founded2008Price Target and Rating Average Price Target for Rhythm Pharmaceuticals$141.12 High Price Target$160.00 Low Price Target$100.00 Potential Upside/Downside+34.8%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.54 million Net Margins-85.59% Pretax Margin-85.14% Return on Equity-159.87% Return on Assets-44.00% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.20 Sales & Book Value Annual Sales$189.76 million Price / Sales37.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book50.34Miscellaneous Outstanding Shares68,530,000Free Float64,490,000Market Cap$7.18 billion OptionableOptionable Beta1.97 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:RYTM) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
